Nilotinib-treated patients with chronic myeloid leukemia had a significantly higher increase in plasma insulin levels per unit of glucose compared to non-CML controls and imatinib-treated patients.
Cross-Sectional (n=42)
No
Does nilotinib therapy impair skeletal muscle glucose handling and insulin sensitivity compared to imatinib and healthy controls in non-diabetic patients with CML?
Nilotinib therapy in non-diabetic CML patients is associated with early signs of decreased skeletal muscle insulin sensitivity and compensatory hyperinsulinemia, highlighting the need for metabolic monitoring to mitigate cardiovascular risk.
Tasa de eventos absoluta: 48% vs 37.2%
valor p: p=0.029
In this study, we have shown that non-diabetic patients with CML receiving nilotinib therapy show early signs of disturbed skeletal muscle glucose handling, which was not observed in imatinib-treated patients. These observations in nilotinib users may reflect decreased muscle insulin sensitivity, which could serve as a potential target to counteract glycemic dysregulation, and is of clinical importance since these patients have an increased cardiovascular disease risk.
Janssen et al. (Wed,) conducted a cross-sectional in Chronic myeloid leukemia (n=42). Nilotinib vs. Imatinib and non-CML controls was evaluated on Increase in plasma insulin levels per unit of glucose (pmol/L) (p=0.029). Nilotinib-treated patients with chronic myeloid leukemia had a significantly higher increase in plasma insulin levels per unit of glucose compared to non-CML controls and imatinib-treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: